RxDoctor Payments DataLook up a doctor →

David Nudell, MD

Pediatric Urology · San Jose, CANPI 1912070889

Payments from drug & device makers

$10,426in general payments, 2019–2025

Across 459 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$2K
  • Sumitomo Pharma America, Inc.$2K
  • Johnson & Johnson$852
  • AbbVie$607
  • Dendreon Pharmaceuticals LLC$561
  • Amgen$385
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$9,34290%
  • Education$1,08410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,426 in reported general payments places this provider in the 90th percentile of 39 pediatric urology providers in California.

See all pediatric urology providers in California

Medicare billing

Part B allowed, 2024
$509,036
Medicare patients
594
Services billed
15,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron97$105,626
GemtesaVibegron87$79,171
Tamsulosin Hcl499$10,232
Finasteride483$9,878
Alfuzosin Hcl ErAlfuzosin Hcl186$5,221
Potassium Citrate ErPotassium Citrate40$4,552
Oxybutynin Chloride ErOxybutynin Chloride88$3,483
Testosterone Cypionate60$3,478
Testosterone36$3,013
NitrofurantoinNitrofurantoin Macrocrystal58$2,965
Solifenacin Succinate18$1,783
Bicalutamide24$1,524
Dutasteride49$1,513
Estradiol18$1,120
Tolterodine Tartrate ErTolterodine Tartrate13$938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$2,172$105,62697 claims
Sumitomo Pharma America, Inc.Gemtesa$1,675$79,17187 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 39 pediatric urology providers in California.

Other pediatric urology in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →